Ipamorelin + CJC‑1295 no‑DAC is a synergistic GH‑pulse blend that users take for recovery, sleep quality, anti‑aging, and body‑composition tweaks such as muscle gain and fat loss. The community’s modal regimen is a daily sub‑cutaneous dose of about 250 µg, with a broader range from 125 µg up to 2.5 mg, and schedules are left to the individual. The only clear trade‑off is that the blend has no FDA‑approved indication, so all human use is off‑label or compounded; sleep‑pattern changes and vivid dreams are the most frequently reported side effect, while injection‑site irritation and other typical peptide reactions have not shown up consistently.
Data last updated
Measured on 3 of 6 axes
Evidence shape
There is no clinical evidence for the Ipamorelin / CJC‑1295 blend; no human studies have been published and no registered trials exist. Consequently, the peptide has zero mapped indications and no completed trials to assess quality or breadth. The complete absence of human data means any claims about efficacy or safety are unsupported by scientific research.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 12 out-of-stock offers not shown
How Ipamorelin / CJC-1295 Blend is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
In the community tier, most users (n=10) follow an unspecified schedule with a typical dose of about 300 mcg (range 150 mcg‑2.5 mg), while a minority dose daily around 250 mcg (n=2), three times daily at 125 mcg (n=1), or weekly at 2 mg (n=1); no cycling pattern was reported.